STOCK TITAN

Crinetics Pharmaceuticals - CRNX STOCK NEWS

Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.

Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company pioneering oral therapies for endocrine disorders and related tumors. This news hub provides investors and industry professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.

Access official press releases, financial reports, and scientific updates related to CRNX's lead candidates: paltusotine for acromegaly/carcinoid syndrome and atumelnant targeting adrenal disorders. Our curated news collection enables efficient tracking of therapeutic innovations in rare diseases, partnership announcements, and market-moving events.

Content spans clinical data publications, FDA communications, executive leadership updates, and research collaborations. Bookmark this page for direct access to primary-source information about CRNX's novel small molecule therapies and their development pathways.

Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
-
Rhea-AI Summary
Radionetics Oncology, Inc. (RADN) completes $52.5 million Series A financing led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, bringing total raised to date to $82.5 million. Paul Grayson joins as CEO, bringing expertise in business strategy, oncology, and G-protein coupled receptor biology. Eric Shiozaki, Ph.D., Partner at DCVC Bio, appointed to the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
management
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.49%
Tags
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) granted non-qualified stock options to six new non-executive employees under the 2021 Inducement Plan. The options have an exercise price of $33.27 per share and will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) to participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference and Piper Sandler 35th Annual Healthcare Conference. Details of the events and webcast accessibility provided. Contact information for arranging in-person meetings also available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) Grants Stock Options to New Non-Executive Employees Under 2021 Inducement Plan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
none
Rhea-AI Summary
Crinetics Pharmaceuticals, Inc. (CRNX) reports successful results for the PATHFNDR-1 Phase 3 study for acromegaly. Anticipates initial data from the Phase 2 study of paltusotine in carcinoid syndrome in December 2023 and topline data from the PATHFNDR-2 study in 1Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
-
Rhea-AI Summary
GordonMD Global Investments LP announces joint investment in Radionetics Oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Radionetics Oncology initiates Phase 1 study for 68Ga-R8760 in adrenocortical carcinoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
Rhea-AI Summary
Crinetics Pharmaceuticals grants non-qualified stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Crinetics Pharmaceuticals

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

2.83B
90.46M
2.09%
110.85%
8.71%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO